Immunotherapy in Combination with Chemotherapy for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks estrogen and progesterone receptors and does not overexpress the human epidermal growth factor receptor 2 (HER2). Previous treatment options for TNBC were limited to chemotherapy alone, resulting in a poor pati...

Täydet tiedot

Tallennettuna:

Bibliografiset tiedot
Muut tekijät:	Meléndez-Solano, Elizabeth, Chapa, Christian, Stevens Barrón, Jazmín Cristina
Aineistotyyppi:	Artículo
Kieli:	en_US
Julkaistu:	2023
Aiheet:	Cancer breast triple negative breast cancer immunotherapy efficacy safety atezolizumab camrelizumab paclitaxel gemcitabine info:eu-repo/classification/cti/2 info:eu-repo/classification/cti/3
Linkit:	https://doi.org/10.2174/1389557523666230517152538 https://pubmed.ncbi.nlm.nih.gov/37198990/
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Lisää ensimmäinen kommentti!

Immunotherapy in Combination with Chemotherapy for Triple-Negative Breast Cancer

Samankaltaisia teoksia